Key Highlights
- Uniquity Bio to advance solrikitug, a monoclonal antibody targeting TSLP.
- $300 million in capital from Blackstone for multiple indications.
- Phase 2 clinical trials to start for COPD and asthma.
- Partnership includes operational agility and scientific rigor.
Source: Business Wire
Notable Quotes
- “Our investment in Uniquity Bio illustrates Blackstone Life Sciences’ commitment to finding, developing and delivering potentially transformative medicines to patients around the world.” — Nicholas Galakatos, Ph.D., Global Head at Blackstone Life Sciences
- “We believe solrikitug has the potential to be a life-changing medication for a significant number of patients who currently have very limited treatment options.” — Brian Lortie, CEO at Uniquity Bio
- “Uniquity Bio’s launch with a Phase 2-ready therapeutic demonstrates our approach of providing expertise and scale capital to our portfolio companies to help them advance their mission.” — Kiran Reddy, MD, Senior Managing Director at Blackstone Life Sciences
SoHC's Take
The launch of Uniquity Bio by Blackstone Life Sciences marks a significant advancement in the field of immunology and inflammation. With the FDA’s acceptance of its Phase 2 IND application for solrikitug and a substantial $300 million investment, Uniquity Bio is poised to address critical unmet needs in respiratory and gastrointestinal indications. The strategic partnership combines the operational agility of a biotech startup with the scientific rigor of a global pharmaceutical company, ensuring a robust pipeline development. This move underscores the growing market potential in immunology, projected to reach $257 billion by 2032, highlighting the importance of innovative therapeutic solutions like solrikitug.
